Extracellular vesicle therapeutics from plasma and adipose tissue
Source abstract
Abstract
Extracellular vesicles (EVs) are cell-released lipid-bilayer nanoparticles that contain biologically active cargo involved in physiological and pathological intercellular communication. In recent years, the therapeutic potential of EVs has been explored in various disease models. In particular, mesenchymal stromal cell-derived EVs have been shown to exert anti-inflammatory, anti-oxidant, anti-apoptotic, and pro-angiogenic properties in cardiovascular, metabolic and orthopedic conditions. However, a major drawback of EV-based therapeutics is scale-up issues due to extensive cell culture requirements and inefficient isolation protocols. An emerging alternative approach to time-consuming and costly cell culture expansion is to obtain therapeutic EVs directly from the body, for example, from plasma and adipose tissue. This review discusses isolation methods and therapeutic applications of plasma and adipose tissue-derived EVs, highlighting advantages and disadvantages compared to cell culture-derived ones.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Cardiovascular Disease and Adiposity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Extracellular vesicles or exosomes? On primacy, precision, and popularity influencing a choice of nomenclature10.1080/20013078.2019.1648167 ↗
2. Lipidomic characterization of extracellular vesicles in human serum10.1177/1849454419879848 ↗
3. Glycan node analysis of plasma-derived extracellular vesicles10.3390/cells9091946 ↗
4. Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability10.1016/j.jprot.2012.03.054 ↗
5. Detection of microRNA expression in human peripheral blood microvesicles10.1371/journal.pone.0003694 ↗
6. Shedding light on the cell biology of extracellular vesicles10.1038/nrm.2017.125 ↗
7. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines10.1080/20013078.2018.1535750 ↗
8. Brain metastases-derived extracellular vesicles induce binding and aggregation of low-density lipoprotein10.1186/s12951-020-00722-2 ↗
9. Extracellular vesicles in cancer detection: hopes and hypes10.1016/j.trecan.2020.09.003 ↗
10. Organotropic drug delivery: synthetic nanoparticles and extracellular vesicles10.1007/s10544-019-0396-7 ↗
11. Extracellular vesicle therapeutics for liver disease10.1016/j.jconrel.2018.01.022 ↗
12. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles10.1146/annurev-cellbio-101512-122326 ↗
13. The role of extracellular vesicles in the progression of neurodegenerative disease and cancer10.1016/j.molmed.2014.04.003 ↗
14. Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells10.3389/fimmu.2014.00556 ↗
15. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin10.1038/ncomms8321 ↗
16. Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function10.4049/jimmunol.0803477 ↗
17. Extracellular vesicles for treatment of solid organ ischemia-reperfusion injury10.1111/ajt.16164 ↗
18. Adipose-derived cellular and cell-derived regenerative therapies in dermatology and aesthetic rejuvenation10.1016/j.arr.2019.100933 ↗
19. Adipose-derived stem cell extracellular vesicles: a systematic review10.1016/j.bjps.2019.03.008 ↗
20. Extracellular vesicles as drug delivery systems: why and how10.1016/j.addr.2020.04.004 ↗
21. Adipose‐derived biogenic nanoparticles for suppression of inflammation10.1002/smll.201904064 ↗
22. What is the blood concentration of extracellular vesicles? Implications for the use of extracellular vesicles as blood-borne biomarkers of cancer
23. International haemovigilance: what have we learned and what do we need to do next10.1111/tme.12582 ↗
24. Lipoprotein-based drug delivery10.1016/j.addr.2020.08.003 ↗
25. Future of high-density lipoprotein infusion therapies: potential for clinical management of vascular disease10.1161/CIRCULATIONAHA.113.002683 ↗
26. Extracellular vesicle-based drug delivery systems for cancer treatment10.7150/thno.37097 ↗
27. Extracellular vesicles versus synthetic nanoparticles for drug delivery10.1038/s41578-020-00277-6 ↗
28. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins10.1007/s00018-018-2773-4 ↗
29. Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid10.3390/cells7120273 ↗
30. Methodological guidelines to study extracellular vesicles10.1161/CIRCRESAHA.117.309417 ↗
31. Residual matrix from different separation techniques impacts exosome biological activity10.1038/srep23550 ↗
32. Isolation of exosomes from blood plasma: qualitative and quantitative comparison of ultracentrifugation and size exclusion chromatography methods10.1371/journal.pone.0145686 ↗
33. Cryogenic transmission electron microscopy nanostructural study of shed microparticles10.1371/journal.pone.0083680 ↗
34. Isolation and characterization of exosomes from cell culture supernatants and biological fluids
35. Measuring circulating cell-derived microparticles10.1111/j.1538-7836.2004.00936.x ↗
36. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum10.1038/s41598-020-57497-7 ↗
37. Reconsidering the quantitative analysis of organic carbon concentrations in size exclusion chromatography10.1016/j.watres.2008.11.025 ↗
38. Size-exclusion chromatography-based isolation minimally alters extracellular vesicles’ characteristics compared to precipitating agents10.1038/srep33641 ↗
39. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes10.1039/C4LC00136B ↗
40. The exosome total isolation chip10.1021/acsnano.7b04878 ↗
41. Microfluidic device for high-throughput affinity-based isolation of extracellular vesicles10.1039/C9LC01190K ↗
42. Plasma and plasma derivatives in therapeutic plasmapheresis: PLASMA FOR THERAPEUTIC APHERESIS10.1111/j.1537-2995.2012.03623.x ↗
43. Recommendations for the use of therapeutic plasma10.2174/157016109787455671 ↗
44. Brightman · N. Y State J. Med · 1946 · 46 · 1835
45. Treatment for emerging viruses: convalescent plasma and COVID-1910.1016/j.transci.2020.102790 ↗
46. Convalescent plasma in Covid-19: possible mechanisms of action10.1016/j.autrev.2020.102554 ↗
47. Plasma exosomes protect the myocardium from ischemia-reperfusion injury10.1016/j.jacc.2015.02.026 ↗
48. Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of non-diabetic exosomesin vitro10.1111/jcmm.13302 ↗
49. Characterization of a purified exosome product and its effects on canine flexor tenocyte biology10.1002/jor.24587 ↗
50. A novel engineered purified exosome product patch for tendon healing: An explant in an ex vivo model
51. Wound healing effects of a curcuma zedoaria polysaccharide with platelet-rich plasma exosomes assembled on chitosan/silk hydrogel sponge in a diabetic rat model10.1016/j.ijbiomac.2018.05.066 ↗
52. Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model10.7150/thno.16803 ↗
53. Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway10.7150/thno.17450 ↗
54. Exosomes isolated from platelet-rich plasma and mesenchymal stem cells promote recovery of function after muscle Injury10.1177/0363546520926462 ↗
55. Exosomes derived from platelet-rich plasma present a novel potential in alleviating knee osteoarthritis by promoting proliferation and inhibiting apoptosis of chondrocyte via Wnt/β-catenin signaling pathway10.1186/s13018-019-1529-7 ↗
56. Exosomes from human umbilical cord blood accelerate cutaneous wound healing through miR-21-3p-mediated promotion of angiogenesis and fibroblast function10.7150/thno.21234 ↗
57. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-2410.1038/s41419-018-0274-x ↗
58. Extracellular vesicles isolated from patients undergoing remote ischemic preconditioning decrease hypoxia-evoked apoptosis of cardiomyoblasts after isoflurane but not propofol exposure10.1371/journal.pone.0228948 ↗
59. Longterm exercise-derived exosomal miR-342-5p: a novel exerkine for cardioprotection10.1161/CIRCRESAHA.118.314635 ↗
60. Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice10.1016/j.cmet.2019.05.015 ↗
61. Analysis of platelet-rich plasma extraction: variations in platelet and blood components between 4 common commercial kits10.1177/2325967116675272 ↗
62. Platelet-rich plasma: the choice of activation method affects the release of bioactive molecules10.1155/2016/6591717 ↗
63. Use of platelet-rich plasma and platelet-rich fibrin in dentistry and oral surgery: introduction and review of the literature10.1177/0898756419876057 ↗
64. Platelet-rich plasma: myth or reality?
65. Use of platelet-rich plasma (PRP) in microsurgery10.1016/j.jormas.2017.05.009 ↗
66. Platelet-rich plasma therapy - future or trend10.1186/ar3914 ↗
67. Ischaemic preconditioning – Current knowledge and potential future applications after 30 years of experience10.1016/j.advms.2016.11.006 ↗
68. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles10.1016/j.yjmcc.2014.01.004 ↗
69. Mechanisms of exercise-induced cardioprotection
70. Muscles, exercise and obesity: skeletal muscle as a secretory organ10.1038/nrendo.2012.49 ↗
71. Rejuvenation of aged progenitor cells by exposure to a young systemic environment10.1038/nature03260 ↗
72. Heterochronic parabiosis: historical perspective and methodological considerations for studies of aging and longevity10.1111/acel.12065 ↗
73. The ageing systemic milieu negatively regulates neurogenesis and cognitive function10.1038/nature10357 ↗
74. Extracellular vesicles: immunomodulatory messengers in the context of tissue repair/regeneration10.1016/j.ejps.2016.09.017 ↗
75. Mesenchymal stem cell-derived exosomes: new opportunity in cell-free therapy10.15171/apb.2016.041 ↗
76. Mesenchymal stem cell exosomes10.1016/j.semcdb.2015.03.001 ↗
77. Adipose-derived exosomes protect the pulmonary endothelial barrier in ventilator-induced lung injury by inhibiting the TRPV4/Ca2+signaling pathway10.1152/ajplung.00255.2019 ↗
78. Role of stem-cell-derived microvesicles in the paracrine action of stem cells10.1042/BST20120192 ↗
79. Exosomes from MiR-126-overexpressing Adscs are therapeutic in relieving acute myocardial ischaemic injury10.1159/000485949 ↗
80. Exosomes derived from miR‐146a‐modified adipose‐derived stem cells attenuate acute myocardial infarction−induced myocardial damage via downregulation of early growth response factor 110.1002/jcb.27731 ↗
81. miR-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage10.1016/j.omtn.2018.01.010 ↗
82. Exosomes from MiR-30d-5p-ADSCs reverse acute ischemic stroke-induced, autophagy-mediated brain injury by promoting M2 microglial/macrophage polarization10.1159/000490078 ↗
83. Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing M2 macrophages and beiging in white adipose tissue10.2337/db17-0356 ↗
84. Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosisviaautophagy activation10.1111/jcmm.13170 ↗
85. The adipose stromal vascular fraction as a complex cellular source for tissue engineering applications10.1089/ten.teb.2017.0061 ↗
86. Higher pericyte content and secretory activity of microfragmented human adipose tissue compared to enzymatically derived stromal vascular fraction: microfragmented adipose tissue secretory activity10.1002/sctm.18-0051 ↗
87. Adipose tissue-derived extracellular fraction characterization: biological and clinical considerations in regenerative medicine10.1186/s13287-018-0956-4 ↗
88. Guanabenz Downregulates Inflammatory Responses via eIF2alpha Dependent and Independent Signaling10.3390/ijms17050674 ↗
89. The solid progress of nanomedicine10.1007/s13346-020-00743-2 ↗
90. Taking the vehicle out of drug delivery10.1016/j.mattod.2017.01.013 ↗
91. Strategies for improving drug delivery: nanocarriers and microenvironmental priming10.1080/17425247.2017.1243527 ↗
92. Multistage vector delivery of sulindac and silymarin for prevention of colon cancer10.1016/j.colsurfb.2015.10.005 ↗
93. A micro/nano composite for combination treatment of melanoma lung metastasis10.1002/adhm.201500910 ↗
94. Porous silicon microparticles for delivery of siRNA therapeutics
95. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone10.1038/s41551-019-0502-4 ↗
96. The molecular mechanisms of obesity paradox10.1093/cvr/cvx106 ↗
97. Influence of body mass index on outcome of the mechanically ventilated patients10.1136/thx.2010.145086 ↗
98. A paradox defined10.4187/respcare.04243 ↗
99. Is body mass index associated with outcomes of mechanically ventilated adult patients in intensive critical units? A systematic review and meta-analysis
100. High-fat feeding protects mice from ventilator-induced lung injury, via neutrophil-independent mechanisms10.1097/CCM.0000000000002403 ↗